Ira Weisberg Named President and Chief Commercial Officer at Endonovo

Endonovo Therapeutics Inc. has appointed Ira Weisberg as president and chief commercial officer of its Medical Division.
 
“Ira will be responsible for expanding global sales and marketing operations, including: business development, acquisitions and fostering product innovation while overseeing advancement of SofPulse and Roma Pulsed Electro Magnetic Frequency (PEMF) medical devices distribution globally,” Chairman and CEO Alan Collier said.
 
Weisberg has more than four decades of experience in healthcare and pharmaceutical management, business development, finance, sales and marketing. His past work experience includes positions as president and CEO of Amherst Pharmaceuticals, senior vice president and corporate development officer at Neurotrope Bioscience. Other executive medical administrative experience include executive positions at ALPHAVAX INC., LIFECYCLE PHARMA, CHUGAI PHARMA USA, HAEMACURE CORPORATION, and AVENTIS BEHRING.
 
Throughout his career, Weisberg led negotiations and signed licensing deals for strategic acquisitions, distribution and development deals for multiple companies in the medical device and pharmaceutical industry. His expertise is in developing strategies to guide emerging medical companies to advance revenue and enhance company diversity, developmental pipelines and geographic reach particularly in fast-growing emerging medical device and pharmaceutical markets.
 
Key to Strategy
“Acquisitions and distribution licensing agreements are a key part of our strategy to complement and grow our SofPulse and Roma PEMF portfolio globally,” according to Collier.
 
As senior business development director with AVENTIS BEHRING, a global leader in recombinant albumin, Weisberg negotiated out-licensing, supply, distribution and development agreements with major pharmaceutical companies in excess of $100 million and contributed to revenues for the company’s specialty product valued at $500 million while assisting the company to be valued more than $750 million.
 
“Simply having Ira’s leadership and his abilities as a lead negotiator and his past performance to close large distribution deals brings a level of gravitas to the company. He understands the unique value proposition our revolutionary medical technology offers medical providers to overcome the global opioid crisis while helping patients everywhere solve pain and inflammation conditions effectively and drug-free. Over the progression of his career, Weisberg has specialized in the marketing, operations and product development with established pharmaceutical and early-stage biotechnology companies (public and private). He has structured, participated in and completed numerous transactions including mergers and acquisitions, equity and joint ventures,” Collier said.
 
Challenging the Medical Status Quo
“I am thrilled to be joining the Endonovo team,” Weisberg stated. “I look forward to applying my experience and industry knowledge to challenge the medical status quo of using narcotics, opioids, NSAID’s and other invasive and unhealthy pain and inflammation treatment solutions by leveraging industry wide distribution of a revolutionary non-invasive medical technology. I’m excited to help guide this effort moving forward.”
 
As vice president of Operations for HAEMACURE CORPORATION, a developer of plasma-derived surgical hemostats and adhesives, Wiesberg established and positioned the company globally through negotiations and signing of multinational licensing and joint venture agreements. He guided growth and generated revenue more than $30 million in an IPO, providing capital for growth and product development.
 
“Having the opportunity to lead negotiations and development for distribution and acquisitions of Endonovo’s PEMF line of medical products is something I could not pass up,” Weisberg said.
 
Endonovo’s current portfolio of assets include SofPulse and Roma PEMF medical devices and 27 patents. The company’s current Electroceutical therapeutic PEMF devices use pulsed short-wave radio frequency at 27.12 MHz. Both medical devices are noninvasive, drug-free and have been U.S. Food and Drug Administration-cleared for the palliative treatment of soft tissue injuries and post-operative pain and edema. Both medical products are CE (European Union) Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema.
 
Aggressive Global Growth Strategy
“With an aggressive global growth strategy and a well-developed diversified sales and marketing directives, I believe that Endonovo’s distribution and sales revenues have the potential of reaching over $100 million in the next few years,” Weisberg concluded.
 
“Through Ira’s guidance, we expect widespread growth in our historic medical sector through our PEMF line of medical devices. His knowledge and ability to negotiate and sign large distribution and development deals fits perfectly into Endonovo’s plans. As such, together we will explore strategic alternatives for investment and expansion amongst larger, better-known participants in the medical device/technology markets,” Collier noted. “This should optimize significant expansion of distribution channels to maximize the shareholder value potential of its SofPulse® Pulsed Electro Magnetic Frequency (PEMF) proprietary assets. We believe that both our legacy medical division and our newly established mergers and acquisitions divisions will grow simultaneously and become more competitive, marketable and financeable to current investors and debtholders, potential investors, partners and other investment opportunities. By evaluating Endonovo as a ‘pure play’ in each discrete sector, we believe that we will obtain a more favorable overall valuation to our shareholders.” 
 
Endonovo Therapeutics is now structured into two divisions: Legacy – a commercial-stage developer primarily of noninvasive wearable Electroceuticals therapeutic devices for pain relief, general wellness and wound curatives with many of its products marketed under the SofPulse brand name; and its Build Up Strategy – acquiring complementary specialty service providers in the construction industry.